Supernus Pharmaceuticals (SUPN) Stock Statistics & Valuation Metrics

Supernus Pharmaceuticals has a market cap or net worth of $2.31B. The enterprise value is $1.29B.

Supernus Pharmaceuticals has 56,073,090 shares outstanding. The number of shares has decreased by -2.65% in one year.

Supernus Pharmaceuticals’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 5.69%.

The current PE Ratio of Supernus Pharmaceuticals is 36.0. Supernus Pharmaceuticals’s PEG ratio is 0.00494.

In the last 12 months, Supernus Pharmaceuticals had revenue of 661.82M and earned 73.86M in profits. Earnings per share was 1.34.

In the last 12 months, operating cash flow was 187.06M and capital expenditures -1.20M, giving a free cash flow of 185.87M billion.

Supernus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Supernus Pharmaceuticals upcoming earnings date is Mar 3, 2026, After Close (Confirmed).

Supernus Pharmaceuticals as a current ratio of 2.35, with Debt / Equity ratio of 3.13%

In the past 12 months, Supernus Pharmaceuticals has paid 24.00M in taxes.

Supernus Pharmaceuticals EV to EBITDA ratio is 10.98, with an EV/FCF ratio of 11.43.

Supernus Pharmaceuticals has $522.60M in cash and marketable securities with $24.38M in debt, giving a net cash position of -$498.21M billion.

Gross margin is 79.49%, with operating margin of 12.34%, and net profit margin of 11.16%.

The average price target for Supernus Pharmaceuticals is $41.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy